Literature DB >> 1206741

Activation in vitro of mouse macrophages by syngeneic, allogeneic, or xenogeneic lymphocyte supernatants.

I J Fidler.   

Abstract

Macrophages from normal C57BL/6 mice, those with a subcutaneous B16 melanoma, and mice immunized against the tumor were examined for in vitro cytotoxicity to B16 tumor cells. Macrophages were treated by incubation with supernatants from B16 cells grown either in unmixed cultures or in cultures containing syngeneic, normal, or sensitized allogeneic (A mouse), or xenogeneic (rat) lymphocytes. The various treated and untreated macrophages were then cultured for 5 days with viable B16 cells prelabeled with 125I-5-iodo-2'-deoxyuridine; the cultures were terminated, and the extent of destruction of the B16 target cells was determined from the amounts of radioactivity remaining in adherent tumor cells. Of the untreated macrophages, only those from immunized mice were cytotoxic to the tumor cells; macrophages from normal and tumor-bearing mice became cytotoxic by incubation with supernatants from cultures containing lymphocytes from immunized syngeneic mice, sensitized allogeneic mice, or sensitized rats; and macrophages incubated with supernatants from cultures containing normal nonsensitized allogeneic or xenogeneic lymphocytes showed no cytotoxicity. Thes results suggested that macrophages from tumor-bearing animals are potentially cytotoxic to their syngeneic tumors and can be activated by mediators released from sensitized syngeneic, allogeneic, and/or xenogeneic lymphocytes in vitro.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1206741     DOI: 10.1093/jnci/55.5.1159

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  14 in total

1.  Modulation of macrophage tumoricidal capability by polyene antibiotics: support for membrane lipid as a regulatory determinant of macrophage function.

Authors:  H A Chapman; J B Hibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

Review 2.  Disordered function of mononuclear phagocytes in malignant disease.

Authors:  R J Sokol; G Hudson
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

3.  In vitro tumor cell killing by peritoneal macrophages from mitomycin C-treated rats.

Authors:  T Ogura; H Shindo; O Shinzato; M Namba; T Masuno; T Inoue; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators.

Authors:  D J Cameron; W H Churchill
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

5.  A macrophage activating factor is present and active in the ascitic fluid of patients with ovarian cancer.

Authors:  M Kaneko; M Nishida; H Iwasaki
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

6.  Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon.

Authors:  W C Koff; W E Fogler; J Gutterman; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.

Authors:  E S Kleinerman; A J Schroit; W E Fogler; I J Fidler
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

8.  Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

Authors:  I J Fidler; S Sone; W E Fogler; Z L Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

9.  Ontogeny of murine macrophages: functions related to antigen presentation.

Authors:  C Y Lu; E R Unanue
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

10.  Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor.

Authors:  L P Svedersky; C V Benton; W H Berger; E Rinderknecht; R N Harkins; M A Palladino
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.